Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis

Abstract

Background:The benefits and risks of offlabel use of recombinant factor VIIa in patients without hemophilia are contested. We performed a systematic review to assess the effectiveness and safety of such use. Methods:We searched electronic databases including MEDLINE, EMBASE and CENTRAL for randomized controlled trials comparing recombinant factor VIIa with placebo in any patient population except those with hemophilia up to January 2010. Eligible articles were assessed for inclusion, data were extracted, and study quality was evaluated. Outcomes included mortality, blood loss, requirements for red blood cell transfusion, number of patients transfused and thromboembolic events. Results:We identified 26 trials: 14 on off-label prophylactic use of recombinant factor VIIa (n = 1137) and 12 on off-label therapeutic use (n = 2538). In the studies on prophylactic use, we found no significant difference in mortality or thromboembolic events between the treatment and placebo groups. We found modest benefits favouring recombinant factor VIIa in blood loss (weighted mean difference −276 mL, 95% confidence interval [CI] −411 to −141 mL), red blood cell transfusion (weighted mean difference −281 mL, 95% CI −433 to −129 mL) and number of patients transfused (relative risk 0.71, 95% CI 0.50 to 0.99). In the therapeutic trials, we found a nonsignificant de crease in mortality and a nonsignificant increase in thromboembolic events but no difference in control of bleeding or red blood cell transfusion.

Use of Activated Recombinant Factor VII in Severe Bleeding – Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding

“…Concordant with the meta-analysis presented by Lin et al [44], all RCTs carried out in these clinical situations have yielded a relative risk for mortality where 95% confidence intervals have included 1.0. It is unlikely that class I data for mortality benefit, which would require an estimated sample size of about 12,000 patients (based on an anticipated mortality in control groups of about 20%) will ever be undertaken.…”

Use of Recombinant Factor Seven (rFVIIa) in the treatment of severe bleeding from trauma

“…Concordant with the meta analysis presented by Lin et al [10], all RCTs carried out in trauma and other situations of massive blood loss in non-haemophiliacs have yielded a relative risk for mortality where 95% confidence intervals have included 1.0. It is unlikely that class I data for mortality benefit, which would require an estimated sample size of about 12,000 patients (based on an anticipated mortality in control groups of about 20%), will ever be undertaken.…”

New Trends in Resuscitation

“…A follow up phase III randomized trial was stopped ahead of schedule (573 out of 1502 patients enrolled) for futility 98 . A meta-analysis of the published literature yielded the same conclusions 99 . Although costly, this drug has logistical appeal for the military and was therefore, used by the US troops fairly aggressively.…”